Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Hartkopf

Showing results (41-50 of 90) with videos related to

Pageof 9
Sort By:
Breast Cancer Research and Treatment|March 5, 2014
Detection and clinical relevance of hematogenous tumor cell dissemination in patients with ductal carcinoma in situMalgorzata Banys, Markus Hahn, Ines Gruber, et al.
Geburtshilfe Und Frauenheilkunde|December 23, 2017
Circulating Tumour Cells, Circulating Tumour DNA and Circulating MicroRNA in Metastatic Breast Carcinoma - What is the Role of Liquid Biopsy in Breast Cancer?Arkadius Polasik, Marie Tzschaschel, Fabienne Schochter, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 18, 2016
Patient-reported outcomes (PRO) focused on adverse events (PRO-AEs) in adjuvant and metastatic breast cancer: clinical and translational implicationsStefan Stefanovic, Markus Wallwiener, Uros Karic, et al.
Archives of Gynecology and Obstetrics|June 18, 2021
Evaluation of sonographic detectability of different markers within an in vitro simulation model of the axillaSelin Guergan, Uta Hoopmann, Carmen Roehm, et al.
Scientific Reports|February 21, 2019
The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancerMalgorzata Banys-Paluchowski, Isabell Witzel, Bahriye Aktas, et al.
Journal of Experimental & Clinical Cancer Research : CR|August 18, 2023
Breast cancer patient-derived microtumors resemble tumor heterogeneity and enable protein-based stratification and functional validation of individualized drug treatmentNicole Anderle, Felix Schäfer-Ruoff, Annette Staebler, et al.
Plos One|September 9, 2025
The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21stcentury: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivorsTatjana Braun, Sophia Huesmann, Kerstin Pfister, et al.
Plos One|November 19, 2025
Study Protocol of SURVIVE HERoes (NCT06643585): Trastuzumab Deruxtecan for molecular relapse in HER2+/ Low early breast cancer with ctDNA positivity after primary therapyKerstin Pfister, Thomas W P Friedl, Andreas Hartkopf, et al.
International Journal of Cancer|March 6, 2024
Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer: Results from the open-label, multicentre, non-interventional BRAWO studyDiana Lüftner, Florian Schuetz, Andreas Schneeweiss, et al.
Oncotarget|September 9, 2017
Tumor biomarker conversion between primary and metastatic breast cancer: mRNA assessment and its concordance with immunohistochemistryStefan Stefanovic, Ralph Wirtz, Thomas M Deutsch, et al.
Pageof 9

Showing results (41-50 of 90) with videos related to

Sort By:
Pageof 9
Breast Cancer Research and Treatment|March 5, 2014
Detection and clinical relevance of hematogenous tumor cell dissemination in patients with ductal carcinoma in situMalgorzata Banys, Markus Hahn, Ines Gruber, et al.
Geburtshilfe Und Frauenheilkunde|December 23, 2017
Circulating Tumour Cells, Circulating Tumour DNA and Circulating MicroRNA in Metastatic Breast Carcinoma - What is the Role of Liquid Biopsy in Breast Cancer?Arkadius Polasik, Marie Tzschaschel, Fabienne Schochter, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 18, 2016
Patient-reported outcomes (PRO) focused on adverse events (PRO-AEs) in adjuvant and metastatic breast cancer: clinical and translational implicationsStefan Stefanovic, Markus Wallwiener, Uros Karic, et al.
Archives of Gynecology and Obstetrics|June 18, 2021
Evaluation of sonographic detectability of different markers within an in vitro simulation model of the axillaSelin Guergan, Uta Hoopmann, Carmen Roehm, et al.
Scientific Reports|February 21, 2019
The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancerMalgorzata Banys-Paluchowski, Isabell Witzel, Bahriye Aktas, et al.
Journal of Experimental & Clinical Cancer Research : CR|August 18, 2023
Breast cancer patient-derived microtumors resemble tumor heterogeneity and enable protein-based stratification and functional validation of individualized drug treatmentNicole Anderle, Felix Schäfer-Ruoff, Annette Staebler, et al.
Plos One|September 9, 2025
The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21stcentury: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivorsTatjana Braun, Sophia Huesmann, Kerstin Pfister, et al.
Plos One|November 19, 2025
Study Protocol of SURVIVE HERoes (NCT06643585): Trastuzumab Deruxtecan for molecular relapse in HER2+/ Low early breast cancer with ctDNA positivity after primary therapyKerstin Pfister, Thomas W P Friedl, Andreas Hartkopf, et al.
International Journal of Cancer|March 6, 2024
Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer: Results from the open-label, multicentre, non-interventional BRAWO studyDiana Lüftner, Florian Schuetz, Andreas Schneeweiss, et al.
Oncotarget|September 9, 2017
Tumor biomarker conversion between primary and metastatic breast cancer: mRNA assessment and its concordance with immunohistochemistryStefan Stefanovic, Ralph Wirtz, Thomas M Deutsch, et al.
Pageof 9